Curocell’s RIMQARTO Injection Secures Full Regulatory Approval, Set to Enter CAR-T Market with 67% Complete Response Rate

Curocell’s RIMQARTO Injection Secures Full Regulatory Approval, Positioned to Enter CAR-T Market with 67% Complete Response Rate South Korean biotechnology company Curocell (KOSDAQ: 372320) has achieved a landmark milestone in…

Read MoreCurocell’s RIMQARTO Injection Secures Full Regulatory Approval, Set to Enter CAR-T Market with 67% Complete Response Rate

TRexBio Initiates Phase 1b Study of TRB-061 with First Patient Dosed in Moderate-to-Severe Atopic Dermatitis

TRexBio Initiates Phase 1b Study of TRB-061 in Moderate-to-Severe Atopic Dermatitis with First Patient Dosed TRex Bio, Inc. (“TRexBio”), a clinical-stage biotechnology company focused on discovering and developing immunoregulatory therapies…

Read MoreTRexBio Initiates Phase 1b Study of TRB-061 with First Patient Dosed in Moderate-to-Severe Atopic Dermatitis

ClearNote Health to Showcase Advanced Early Detection Results for Avantect® Pancreatic Cancer Test at Digestive Disease Week 2026

ClearNote Health to Showcase Leading Early Detection Results for Avantect® Pancreatic Cancer Test at Digestive Disease Week 2026 ClearNote Health, a biotechnology company focused on advancing early cancer detection, has…

Read MoreClearNote Health to Showcase Advanced Early Detection Results for Avantect® Pancreatic Cancer Test at Digestive Disease Week 2026

Study Reveals Growing Public Optimism for Scientific Breakthroughs Alongside Increasing Concerns About the Pace of Global Change

Study Reveals Growing Public Optimism for Scientific Breakthroughs Amid Increasing Concerns Over the Pace of Global Change A new global report developed by Leaps by Bayer in collaboration with Boston…

Read MoreStudy Reveals Growing Public Optimism for Scientific Breakthroughs Alongside Increasing Concerns About the Pace of Global Change

Ray Therapeutics Secures European Medicines Agency PRIME Designation for RTx-015 in Retinitis Pigmentosa

Ray Therapeutics Secures PRIME Designation from the European Medicines Agency for RTx-015 Targeting Retinitis Pigmentosa Ray Therapeutics (RayTx), a clinical-stage biopharmaceutical company focused on developing innovative therapies for vision restoration,…

Read MoreRay Therapeutics Secures European Medicines Agency PRIME Designation for RTx-015 in Retinitis Pigmentosa